Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new combination of medicines, DSP107 and atezolizumab, compared to an existing treatment, fruquintinib, for adults with advanced microsatellite stable MSS colorectal cancer. This Phase 2b study focuses on patients whose cancer has progressed or who cannot tolerate standard therapies. The study aims to assess whether the new combination improves patient outcomes while monitoring safety and how the body processes these treatments. Participants will be randomly assigned to one of two groups. One group receives DSP107 intravenously on Days 1, 8, and 15, plus atezolizumab intravenously on Day 1 of each 28-day cycle. The other group takes fruquintinib orally once daily for 21 days, followed by 7 days off, in 28-day cycles. The treatment period can last up to 24 cycles, with adjustments made based on tolerance. After treatment, a safety follow-up of up to 90 days will occur, followed by long-term follow-up for up to five years. During the study, participants will have regular assessments including evaluations of overall survival, adverse events, heart function via ECG, blood pressure, pulse rate, quality of life, and immune response to DSP107. Participants keep dosing diaries if taking fruquintinib. The study includes screening lasting up to 28 days before treatment starts. Total participation time depends on treatment response and tolerability, with ongoing monitoring throughout and after the treatment phase.
Actively Recruiting
Researchers are observing the safety and performance of Terumo Aortic endovascular grafts used to treat patients with aortic aneurysms and other related conditions during routine clinical practice. This global, multi-center registry collects real-world data to better understand outcomes after these devices have been approved and are in use. The study is open label and includes multiple groups based on the type of aneurysm or device implanted. Participants receive one of several types of Terumo Aortic endovascular stent-grafts, including Thoracic Relay stent grafts, Abdominal Anaconda or Treo grafts, custom fenestrated devices, and Iliac artery-specific implants. These devices are CE marked or custom-made and are implanted following standard clinical procedures. The registry tracks patients treated with these devices in usual care settings without altering treatment. During the study, participants will attend follow-up visits where researchers collect safety data, patient-reported outcomes, and health economic information. Key outcomes measured include aortic-related mortality within 30 days post-implant, technical success on the day of surgery, and composite clinical success and additional endpoints at one year. The registry aims to monitor long-term performance and safety of these grafts in real-world use, with participation lasting as determined by follow-up schedules.